Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences

Rhea-AI Summary

Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that CEO Jasbir S. Seehra, Ph.D., will participate in two healthcare conferences. The events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 11:00 AM ET as a fireside chat, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 starting at 7:00 AM ET as a corporate presentation. Both presentations will be accessible online and archived on Keros' investor website for 90 days.

LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in two upcoming healthcare conferences.

Presentation Details:

Event: Morgan Stanley 19^th Annual Global Healthcare Conference
Date/Time: Friday, September 10 at 11:00 AM ET
Format: Fireside Chat

Event: H.C. Wainwright 23^rd Annual Global Investment Conference
Date/Time: Available on Monday, September 13 starting at 7:00 AM ET
Format: Corporate Presentation

The Morgan Stanley fireside chat presentation will be webcast live at https://morganstanley.webcasts.com/starthere.jsp?ei=1488923&tp_key=f6a26a9322 and the H.C. Wainwright presentation will be available at https://journey.ct.events/view/2af63db8-a98e-40f7-bb4e-4fc6d4b18ba0. Both will be archived in the Investors section of the Keros website at https://ir.kerostx.com/. A replay will be available for 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Investor Contact:

Mike Biega
mbiega@soleburytrout.com 
(617) 221-9660

FAQ

When will Keros Therapeutics present at the Morgan Stanley Healthcare Conference?

Keros Therapeutics will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 11:00 AM ET.

What is the format of the Keros presentation at the Morgan Stanley Conference?

The presentation at the Morgan Stanley Conference will be a fireside chat.

What will Keros present at the H.C. Wainwright Conference?

Keros Therapeutics will have a corporate presentation available on September 13 starting at 7:00 AM ET.

How can I access the Keros Therapeutics conference presentations?

The presentations will be webcast live and archived on Keros' investor website, accessible for 90 days after each event.

What is the focus of Keros Therapeutics' product development?

Keros Therapeutics focuses on therapies for hematological and musculoskeletal disorders, including anemia and cytopenias.